Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R. Crespiatico I, et al. Among authors: aroldi a. Blood. 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. Blood. 2024. PMID: 38194688
Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Gambacorti-Passerini C, et al. Among authors: aroldi a. Am J Hematol. 2016 Jan;91(1):67-75. doi: 10.1002/ajh.24247. Am J Hematol. 2016. PMID: 26588811 Free article. Review.
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R. Andriani A, et al. Among authors: aroldi a. Hematol Oncol. 2019 Aug;37(3):291-295. doi: 10.1002/hon.2635. Epub 2019 May 30. Hematol Oncol. 2019. PMID: 31050810
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Elli EM, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E, Maffioli M, Gardellini A, Carraro MC, D'Adda M, Polverelli N, Rossi M, Orofino N, Carrer A, Gambacorti-Passerini C, Antolini L, Passamonti F. Elli EM, et al. Among authors: aroldi a. Br J Haematol. 2019 Sep;186(5):e123-e126. doi: 10.1111/bjh.15964. Epub 2019 May 20. Br J Haematol. 2019. PMID: 31106402 Free article. No abstract available.
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, Verga L, Fontana D, Sharma GG, Mologni L, Mussolin L, Piazza R, Gambacorti-Passerini C. Bossi E, et al. Among authors: aroldi a. Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3. Am J Hematol. 2020. PMID: 32808682 Free article. Clinical Trial. No abstract available.
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D, Ramazzotti D, Aroldi A, Redaelli S, Magistroni V, Pirola A, Niro A, Massimino L, Mastini C, Brambilla V, Bombelli S, Bungaro S, Morotti A, Rea D, Stagno F, Martino B, Campiotti L, Caocci G, Usala E, Merli M, Onida F, Bregni M, Elli EM, Fumagalli M, Ciceri F, Perego RA, Pagni F, Mologni L, Piazza R, Gambacorti-Passerini C. Fontana D, et al. Among authors: aroldi a. Hemasphere. 2020 Nov 6;4(6):e497. doi: 10.1097/HS9.0000000000000497. eCollection 2020 Dec. Hemasphere. 2020. PMID: 33196013 Free PMC article.
98 results